3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Neoplasm Metastasis
7
Lung Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Ovarian Neoplasms
5
Melanoma
5
Carcinoma, Renal Cell
5
Skin Neoplasms
4
Fallopian Tube Neoplasms
4
Carcinoma
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Mouth Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Interventions
atezolizumab
3
fludarabine
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Pemetrexed
2
Nivolumab
2
Cisplatin
2
spartalizumab
1
repotrectinib
1
pertuzumab
1
lutetium Lu 177 dotatate
1
gilteritinib
1
enzalutamide
1
durvalumab
1
copper dotatate CU-64
1
cemiplimab
1
Trastuzumab
1
Sodium Chloride
1
Radiotherapy
1
Radiosurgery
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Injections
1
Idarubicin
1
HuMax-IL8
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Histologic Type
×
cemiplimab
×
Clear all
NCT06463665
2025-09-26
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled